Oncologists report that patient out-of-pocket costs can impact form of
CALIFON, NJ, May 5 /CNW/ - PediatRx, Inc. (OTCBB: PEDX), a hospital
specialty company with a focus on oncology supportive care, released
poll data today showing that 98% of physician respondents said at least
some of their patients are using co-pay assistance programs for
cancer-related prescription medications. The poll was conducted by
PediatRx in collaboration with Sermo and all respondents were either
oncologists or other physician specialists who treat patients with
Co-pay assistance programs can provide financial assistance to insured,
as well as uninsured, patients to help cover patient out-of-pocket
expenses for prescription medications.
Nearly 2 out of every 3 oncologists polled said that 20% or more of
their patients are using co-pay assistance programs for their
PediatRx markets GRANISOL, the only once-daily FDA-approved oral
solution of granisetron, a medication used to prevent nausea and
vomiting in patients undergoing chemotherapy or radiotherapy for
cancer. PediatRx offers a co-pay assistance program that can help
non-Medicaid or non-Medicare patients pay for GRANISOL. This program,
"GRANI Cares," covers the cost of the copay for the patient, has no
income ceiling, and has no limit on the number of prescriptions that
The poll also addressed costs of anti-nausea therapies. Three out of 4
participating oncologists reported that they would switch patients
currently taking an intravenous or an oral anti-nausea agent to the
oral solution if there were no out-of-pocket costs for the oral
solution. This finding emphasizes the importance of minimizing patient
out-of-pocket costs on physician prescribing of oral formulations if
Co-pay assistance programs, like GRANI Cares, can provide patient access
to cancer-related prescription medications. "If patients cannot afford
their medication and do not fill their prescription, then the
medication cannot help them. That's why we developed GRANI Cares--to
help patients get access to GRANISOL to prevent uncomfortable nausea
and vomiting," said Dr. Cameron Durrant, the founder of PediatRx.
The poll questions were conducted using Sermo, the largest active social
network of verified US physicians.
*12% (n=12) said 60-100% of their patients use co-pay assistance program,
while 22% (n=22) said 40-60%, 29% (n=30) said 20-40%, 35% (n=36) said
1-20%, and 2% (n=2) said none of their patients use co-pay assistance
For the PediatRx co-pay program for GRANISOL, GRANI Cares, please
For disclaimer information, visit: http://www.121hm.com/offers/granisol/tandc.html
GRANISOL is indicated for the prevention of:
Nausea and vomiting associated with initial and repeat courses of
emetogenic cancer therapy, including high-dose cisplatin.
Nausea and vomiting associated with radiation, including total body
irradiation and fractionated abdominal radiation.
For full prescribing information, visit: http://www.pediatrx.com/products/pdf/granisol_pi.pdf
Selected Safety Information
GRANISOL is contraindicated in patients with known hypersensitivity to
the drug or any of its components.
QT prolongation has been reported with granisetron. Therefore, GRANISOL
Oral Solution should be used in caution with patients with pre-existing
arrhythmias or cardiac conduction disorders, as this might lead to
clinical consequences. Patients with cardiac disease, on cardio-toxic
chemotherapy, with concomitant electrolyte abnormalities and/or on
concomitant medications that prolong the QT interval are particularly
Safety and effectiveness in pediatric patients have not been
The most common side effects observed with administration of granisetron
were headache, asthenia, constipation, diarrhea, dyspepsia, and
For further information related to material contained in this release,
please contact Holmes World Media Inc., +1 512 981 7369
About PediatRx, Inc..
PediatRx, Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical company which focuses on
treatments for patients suffering from serious conditions requiring
hospitalization. PediatRx trades on the OTCBB under the ticker symbol
Sermo is the largest online physician community, where over 120,000
physicians collaborate to improve patient care. Sermo provides access
to its community for clients that need fast, actionable insights.
PD 53 (05/11)
SOURCE PediatRx Inc.
For further information:
Research & Business Development
+1 908 975 0753